Douglas Carr
Finanzdirektor/CFO bei CENTURY THERAPEUTICS, INC.
Vermögen: 999 567 $ am 30.04.2024
Aktive Positionen von Douglas Carr
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CENTURY THERAPEUTICS, INC. | Finanzdirektor/CFO | 02.02.2024 | - |
Geschäftsführer | 01.10.2018 | - | |
Unternehmenssekretär | 01.10.2018 | - |
Karriereverlauf von Douglas Carr
Ehemalige bekannte Positionen von Douglas Carr
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Century Therapeutics, Inc. /Old/
Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Finanzdirektor/CFO | - | - |
MERCK & CO., INC. | Corporate Officer/Principal | - | - |
Zocor Ltd. | Corporate Officer/Principal | - | - |
Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Comptroller/Controller/Auditor | 09.03.2010 | - |
Ausbildung von Douglas Carr
Rutgers State University of New Jersey | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Frankreich | 2 |
Vereinigtes Königreich | 2 |
Operativ
Corporate Officer/Principal | 2 |
Director of Finance/CFO | 2 |
Comptroller/Controller/Auditor | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
CENTURY THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Health Technology |
Zocor Ltd. | |
Century Therapeutics, Inc. /Old/
Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Health Technology |
- Börse
- Insiders
- Douglas Carr
- Erfahrung